Zero ad trackers.We never sell your data.Healthcare professional?Clinician Resources
A radiologist in a white coat points to a chest X-ray.

ALK-Positive Lung Cancer Treatments Compared

7 FDA-approved drugs, plus 1 in development, side by side from the current prescribing labels. Newest label Nov 2026. Checked November 18, 2026.

The photo: The main trial results on this page were read from scans. Response rates, progression-free survival and brain responses all come from reviewers comparing a person's images over time.

The full ALK-Positive Lung Cancer guide, with open trials and help paying →

Metastatic cancer, first or later ALK treatmentXalkori · Zykadia · Alunbrig · Lorbrena
Metastatic cancer and after surgery for early-stage cancerAlecensa
Advanced cancer, first ALK treatment onlyEnsacove
Advanced cancer after earlier ALK inhibitorsNelkarmi

The FDA has approved 7 ALK inhibitor pills for ALK-positive lung cancer, and each label ties it to a stage, from after surgery to after earlier ALK drugs stop working.

  • ALK-positive means the tumor carries a change in the ALK gene, most often joined to a gene called EML4, that keeps the cancer cells growing. All 7 medicines block that signal and are taken by mouth at home.
  • Xalkori, Zykadia, Alecensa, Alunbrig and Lorbrena are approved for metastatic ALK-positive lung cancer with no limit on earlier treatment. Ensacove is approved only for people who have not taken an ALK inhibitor.
  • Nelkarmi (neladalkib), granted accelerated approval on November 17, 2026, is approved only after earlier ALK inhibitors. Alecensa is the only one approved after surgery, taken for 2 years.
  • Alecensa, Alunbrig, Lorbrena and Ensacove each beat crizotinib (Xalkori) on progression-free survival in its own first-line trial. Progression-free survival is the time before the cancer grew or the person died.
  • None of the 7 labels reports a trial comparing Alecensa, Alunbrig, Lorbrena and Ensacove with each other as a first treatment. Their results in the table therefore do not rank them.
  • None of the 7 labels carries a boxed warning, and each lists its own set of warnings, such as Lorbrena's effects on mood and thinking and Alunbrig's early lung inflammation.

Latest for ALK-positive lung cancer

See all trialsThe week in rare disease

Each date is the day a change was posted. Open an item to see where things stand now.

Free email alert

Follow ALK-positive lung cancer treatment news by email

You get one email when the FDA acts on one of these treatments, a label changes or a new trial opens.

You'll get trial alerts and disease updates for ALK-Positive Lung Cancer, and you can turn either off anytime. We never share your email. Privacy policy

Where are you in ALK-positive lung cancer treatment?

FDA labels describe ALK-positive lung cancer by stage and by which ALK inhibitors came before. A first-line treatment is the first one given for advanced cancer, meaning cancer that has spread or cannot be removed by surgery. Each choice shows the medicines with at least 1 FDA-approved use at that stage. The Xalkori, Zykadia, Alecensa, Alunbrig and Lorbrena labels cover metastatic cancer without limiting what came before. They appear under both of the first 2 choices, even though only some were tested after another ALK inhibitor. Only the Ensacove and Nelkarmi labels also cover locally advanced cancer that cannot be removed by surgery. A care team can confirm which uses fit a person's own history. The filter applies to the 3 tables and the calendar below.

Side by side

7 approved ALK-positive lung cancer treatments at a glance

How each drug is given, how often, who it is approved for and when it was first approved, from the current FDA label.

ALK-Positive Lung Cancer treatments compared: route, schedule, approved use and approval date
DrugHow it is givenHow oftenApproved forFirst approved
crizotinib
Pfizer
Capsule twice a day at home, or oral pellets for adults who cannot swallow capsules250mg twice daily with or without food, until the cancer grows or side effects become too hard to manage; pellets are 250mg (2 shells of 50mg and 1 of 150mg) twice dailyAdults with metastatic ALK-positive or ROS1-positive lung cancer, with no limit on earlier treatment; also relapsed or refractory ALK-positive ALCL in children 1 year and older and young adults, and ALK-positive IMT that cannot be removed by surgery, has come back or has not responded, in adults and children 1 year and olderAugust 26, 2011
ceritinib
Novartis
Tablet once a day with food at home450mg (3 tablets of 150mg) once daily with food, until the cancer grows or side effects become too hard to manageAdults with metastatic ALK-positive lung cancer, with no limit on earlier treatmentApril 29, 2014
alectinib
Genentech (Roche)
Capsule twice a day with food at home600mg (4 capsules of 150mg) twice daily with food; after surgery for a total of 2 years unless the cancer comes back or side effects become too hard to manage; for metastatic cancer until it grows or side effects become too hard to manageAdults after surgery has removed ALK-positive lung cancer with tumors 4cm or larger or cancer in the lymph nodes (adjuvant treatment), and adults with metastatic ALK-positive lung cancerDecember 11, 2015
brigatinib
Takeda
Tablet once a day at home, starting at a lower dose for 7 days90mg once daily for 7 days, then 180mg once daily, with or without food, until the cancer grows or side effects become too hard to manageAdults with metastatic ALK-positive lung cancer, with no limit on earlier treatmentApril 28, 2017
lorlatinib
Pfizer
Tablet once a day at home100mg once daily with or without food, until the cancer grows or side effects become too hard to manageAdults with metastatic ALK-positive lung cancer, with no limit on earlier treatmentNovember 2, 2018
ensartinib
Xcovery
Capsule once a day at home225mg once daily with or without food, until the cancer grows or side effects become too hard to manageAdults with locally advanced or metastatic ALK-positive lung cancer who have not taken an ALK inhibitor beforeDecember 18, 2024
neladalkib
Nuvalent (GSK)
Tablet once a day at home150mg once daily at the same time each day, with or without food, until the cancer grows or side effects become too hard to manageAdults with locally advanced or metastatic ALK-positive lung cancer after alectinib as the only earlier ALK inhibitor, or after 2 or more ALK inhibitors and platinum chemotherapy, given for advanced disease (accelerated approval)November 17, 2026
The evidence

What the pivotal ALK-positive lung cancer trials showed

The primary result from the trial each FDA approval rests on, as reported on the label.

ALK-Positive Lung Cancer pivotal trial results by drug
DrugPivotal trialPrimary result
crizotinib
Pfizer
PROFILE 1014, 343 people with metastatic ALK-positive lung cancer and no earlier treatment for advanced disease, randomized against pemetrexed with cisplatin or carboplatin chemotherapy
Trial record or paper
Median progression-free survival 10.9 vs 7.0 months on chemotherapy (hazard ratio 0.45); 74% vs 45% responded; no statistically significant difference in overall survival, with 84% of the chemotherapy group later taking Xalkori
ceritinib
Novartis
ASCEND-4, 376 people with no earlier treatment for metastatic ALK-positive lung cancer, randomized against pemetrexed with cisplatin or carboplatin chemotherapy; Zykadia was given at the older 750mg fasting dose
Trial record or paper
Median progression-free survival 16.6 vs 8.1 months on chemotherapy (hazard ratio 0.55); 73% vs 27% responded; brain tumors shrank in 57% of 28 vs 22% of 27
alectinib
Genentech (Roche)
ALEX, 303 people with advanced ALK-positive lung cancer and no earlier treatment for it, randomized against crizotinib; ALINA, 257 people after surgery, randomized against platinum chemotherapy
Trial record or paper
ALEX: median progression-free survival 25.7 vs 10.4 months on crizotinib (hazard ratio 0.53), brain tumors shrank in 81% of 21 vs 50% of 22. ALINA: cancer came back, a new lung cancer appeared or the person died in 12% vs 39% on chemotherapy (hazard ratio 0.24)
brigatinib
Takeda
ALTA-1L, 275 people with advanced ALK-positive lung cancer who had not taken an ALK inhibitor, randomized against crizotinib
Trial record or paper
Median progression-free survival 24.0 vs 11.0 months on crizotinib (hazard ratio 0.49); 74% vs 62% responded; brain tumors shrank in 78% of 18 vs 26% of 23
lorlatinib
Pfizer
CROWN, 296 people with advanced ALK-positive lung cancer and no earlier treatment for it, randomized against crizotinib; Study B7461001, 215 people after 1 or more ALK inhibitors, single arm
Trial record or paper
CROWN: cancer grew or the person died in 28% vs 59% on crizotinib (hazard ratio 0.28), median progression-free survival not reached vs 9.3 months; brain tumors shrank in 82% of 17 vs 23% of 13. After earlier ALK inhibitors: 48% responded, and responses lasted a median of 12.5 months
ensartinib
Xcovery
eXalt3, 290 people with advanced ALK-positive lung cancer who had not taken an ALK inhibitor, randomized against crizotinib
Trial record or paper
Median progression-free survival 25.8 vs 12.7 months on crizotinib (hazard ratio 0.56); 74% vs 67% responded; brain tumors shrank in 59% of 17 vs 21% of 24; no statistically significant difference in overall survival (median 63.2 vs 55.7 months)
neladalkib
Nuvalent (GSK)
ALKOVE-1, single arm, 222 people: 67 after alectinib alone and 155 after 2 or more ALK inhibitors and platinum chemotherapy
Trial record or paper
49% responded after alectinib alone and 32% after 2 or more ALK inhibitors; 52% and 51% of responders were still responding at 12 months; brain tumors shrank in 55% of 20 and 26% of 53
Safety

ALK-Positive Lung Cancer treatment side effects and warnings

None of these drugs carries a boxed warning. Each label's main precautions are listed. Side effect rates show how many people in each drug's trials reported each one, whether or not the drug caused it.

ALK-Positive Lung Cancer treatments: most common side effects and key warnings from the FDA labels
DrugMost common side effectsKey warning
crizotinib
Pfizer
vision changes 71%, diarrhea 61% and nausea 56%No boxed warning. Liver injury (fatal in 0.1% of 1,719 people), lung inflammation, QT prolongation (a heart rhythm change), slow heart rate, severe vision loss, harm to an unborn baby, and severe stomach and bowel effects in children and young adults with ALCL and in children with IMT.
ceritinib
Novartis
diarrhea 59%, nausea 43% and vomiting 38%No boxed warning. Stomach and bowel effects, liver injury, lung inflammation, QT prolongation (a heart rhythm change), high blood sugar, slow heart rate, pancreatitis and harm to an unborn baby.
alectinib
Genentech (Roche)
liver test changes or liver injury 41%, constipation 39% and tiredness 36%No boxed warning. Liver injury, lung inflammation, kidney problems, slow heart rate, severe muscle pain with a rise in CPK (a muscle enzyme), hemolytic anemia (red blood cells breaking down too early), very high triglycerides leading to pancreatitis and harm to an unborn baby.
brigatinib
Takeda
diarrhea 53%, rash 40% and cough 35%No boxed warning. Lung inflammation, which can start in the first week (5.1% in ALTA-1L), high blood pressure, slow heart rate, vision problems, rises in CPK (a muscle enzyme) and pancreas enzymes, liver problems, high blood sugar, sun sensitivity and harm to an unborn baby.
lorlatinib
Pfizer
swelling 56%, nerve damage in the hands and feet 44% and weight gain 31%No boxed warning. Not used with strong CYP3A inducers such as rifampin because of severe liver injury. Nervous system effects (52%), including seizures, psychotic effects and changes in thinking, mood (including suicidal thoughts), speech and sleep, high cholesterol and triglycerides, heart rhythm block, lung inflammation, high blood pressure, high blood sugar and harm to an unborn baby.
ensartinib
Xcovery
rash 66%, muscle and joint pain 36% and cough 31%No boxed warning. Not used after a severe allergic reaction to Ensacove or to tartrazine, a dye in the 100mg capsule. Lung inflammation, liver problems, skin reactions (80%), slow heart rate, high blood sugar, vision problems, CPK (a muscle enzyme) rise, high uric acid and harm to an unborn baby.
neladalkib
Nuvalent (GSK)
liver problems 57%, muscle and joint pain 33% and constipation 28%No boxed warning. Liver problems (grade 3 in 18% and grade 4 in 7% of 700 people), kidney problems, eye problems including rare retinal detachment, CPK (a muscle enzyme) rise and harm to an unborn baby.
Not yet approved

ALK-positive lung cancer treatments in clinical trials

Investigational drugs in Phase 1 to 3 trials shown separately because their results are not from an FDA label. Status as of the date in each row.

ALK-Positive Lung Cancer drugs not FDA-approved
DrugStatusHow it works and is givenPivotal trialResult so farWhat is next
Phase 1as of November 18, 2026Kinase inhibitor approved for FLT3-mutated acute myeloid leukemia; the Astellas trial record says it also blocks changed forms of ALKTablet by mouth once a day in 28-day cycles; trial dose not yet setNCT07140016, Phase 1b, about 40 people whose cancer grew after alectinib as the only ALK inhibitor, or after lorlatinibPrimary endpoint: Dose-limiting side effects and other safety measures
ClinicalTrials.gov
No trial results published yetPrimary completion estimated December 31, 2029 on ClinicalTrials.gov; recruiting at 9 of 10 US sites plus sites in France and Spain
Cost

Help paying for ALK-positive lung cancer treatment

Drugmaker copay and free-drug programs, plus charity funds for the condition, checked every week.

Insurance said no? Your Insurer Denied a Rare Disease Drug and Fewer Than 1 in 100 People Appeal, So Here Is the Playbook · 14 min read
Follow ALK-Positive Lung Cancer treatment news by email

One email when the FDA acts on a ALK-Positive Lung Cancer treatment, a label changes or a new trial opens. Never a newsletter.

You'll get, for ALK-Positive Lung Cancer:
  • Trial Alerts, when a new trial opens or a trial changes
  • Disease Updates, FDA decisions and condition news, usually 1 or 2 emails a month
Turn either off anytime from the link in every email.
We never share your email. Unsubscribe anytime. Privacy policy · Check any health site
Questions

ALK-Positive Lung Cancer treatment questions people ask

Which ALK inhibitor is best for ALK-positive lung cancer?

No trial has shown that one ALK inhibitor is best, and none of the 7 labels reports a trial comparing the newer first-line drugs with each other.

What was compared: Alecensa in ALEX, Alunbrig in ALTA-1L, Lorbrena in CROWN and Ensacove in eXalt3 were each tested against crizotinib (Xalkori) in people new to ALK inhibitors. Each label reports a longer progression-free survival than crizotinib, the time before the cancer grew or the person died.

The one matchup of newer drugs: Alunbrig and Alecensa were compared in ALTA-3, in people whose cancer had grown on crizotinib. Results posted on ClinicalTrials.gov show no statistically significant difference in progression-free survival (19.3 vs 19.2 months) or overall survival.

Still running: ALKAZAR is comparing Nelkarmi (neladalkib) with Alecensa as a first treatment and has not reported results.

What differs: Dose schedules, side effects and the tests each label calls for, which are worth going over with an oncologist.

More: Alecensa, Alunbrig, Lorbrena and Ensacove

Source: Alecensa label, DailyMed, August 2026; Alunbrig label, DailyMed, January 2026; Lorbrena label, DailyMed, June 2026; Ensacove label, DailyMed, February 2026; ClinicalTrials.gov NCT03596866; ClinicalTrials.gov NCT06765109

Alecensa vs Lorbrena: what is the difference?

Both are ALK inhibitor pills approved for metastatic ALK-positive lung cancer, but only Alecensa is also approved after surgery, and they have different schedules and side effects.

How it is taken: Alecensa is 600mg, 4 capsules, twice a day with food. Lorbrena is 100mg, 1 tablet, once a day with or without food.

Trial results: In ALEX, median progression-free survival was 25.7 months on Alecensa and 10.4 months on crizotinib. In CROWN, the cancer grew or the person died in 28% on Lorbrena and 59% on crizotinib, and the Lorbrena median had not been reached. No trial in either label compared Alecensa with Lorbrena.

Brain: Brain tumors shrank in 81% of 21 people on Alecensa in ALEX and 82% of 17 on Lorbrena in CROWN, in separate small groups.

Side effects: The most common on Alecensa were liver test changes (41%), constipation (39%) and tiredness (36%). On Lorbrena they were swelling (56%), nerve damage in the hands and feet (44%) and weight gain (31%). Nervous system effects, including seizures, psychotic effects and changes in thinking, mood, speech or sleep, occurred in 52% on Lorbrena.

Tests: Alecensa calls for liver tests every 2 weeks for the first 3 months, muscle enzyme (CPK) tests every 2 weeks for the first month, and triglyceride checks. Lorbrena calls for cholesterol and triglyceride tests, heart rhythm tracings, and blood pressure and blood sugar checks. Lorbrena can also make hormonal birth control stop working.

More: Alecensa drug page and Lorbrena drug page

Source: Alecensa label, DailyMed, August 2026; Lorbrena label, DailyMed, June 2026

What is the next ALK drug after Lorbrena stops working?

No ALK inhibitor label reports a trial in people whose cancer grew on Lorbrena as their only ALK drug. Nelkarmi, the newest approval, covers people after Lorbrena only when they have had 2 or more ALK inhibitors and platinum chemotherapy.

Nelkarmi: Approved for advanced cancer after alectinib alone, or after 2 or more ALK inhibitors plus platinum chemotherapy. In ALKOVE-1, 95% of the 155 people in the second group had taken lorlatinib, and tumors shrank in 32%.

Lorbrena first: Someone whose only ALK inhibitor was Lorbrena does not fall into either Nelkarmi group in the label.

Trials: Studies open to people who took lorlatinib include Astellas's gilteritinib study, TRIANA's TRI-611, NXP900 given with lorlatinib and Chugai's AQUA07. Each has its own rules on which drugs came before.

Testing: LUNGevity says doctors will likely recommend a new biopsy to find what is causing the resistance before recommending another drug.

Questions for the oncologist: Whether a new biopsy or blood test found a resistance change such as G1202R, and which approved uses and trials fit the treatment history.

More: Nelkarmi drug page and ALK-positive lung cancer trials

Source: Nelkarmi label, Nuvalent, November 2026; FDA, November 17, 2026; ClinicalTrials.gov NCT07140016; ClinicalTrials.gov NCT07491497; ClinicalTrials.gov NCT07784959; ClinicalTrials.gov NCT07617337; LUNGevity, About ALK-positive lung cancer

Which ALK inhibitors work for brain metastases?

Every label except Xalkori's reports brain responses, meaning tumors in the brain and spinal cord (the central nervous system) shrank on scans. Each number comes from a small group in a separate trial.

First treatment: Brain tumors shrank in 81% of 21 people on Alecensa, 78% of 18 on Alunbrig, 82% of 17 on Lorbrena and 59% of 17 on Ensacove. On crizotinib in the same trials, the rate was 21% to 50%. On Zykadia it was 57% of 28, against 22% on chemotherapy.

After earlier ALK inhibitors: Brain tumors shrank in 60% of 89 on Lorbrena, and in 61% of 51 on Alecensa and 67% of 18 on Alunbrig after crizotinib. On Nelkarmi they shrank in 55% of 20 after alectinib alone and 26% of 53 after 2 or more ALK inhibitors.

Growth in the brain: In ALEX, the brain was the first place the cancer grew in 12% on Alecensa and 45% on crizotinib.

Xalkori: Its own label reports no brain response results.

More: ALK-positive lung cancer guide

Source: Alecensa label, DailyMed, August 2026; Alunbrig label, DailyMed, January 2026; Lorbrena label, DailyMed, June 2026; Ensacove label, DailyMed, February 2026; Zykadia label, DailyMed, October 2026; Nelkarmi label, Nuvalent, November 2026; Xalkori label, DailyMed, October 2026

What is the newest ALK inhibitor for lung cancer?

Nelkarmi (neladalkib), granted accelerated approval by the FDA on November 17, 2026, is the newest ALK inhibitor on this page.

Who it is for: Adults with locally advanced or metastatic ALK-positive lung cancer whose only earlier ALK inhibitor was alectinib. The label also covers people who have had 2 or more ALK inhibitors and platinum chemotherapy for advanced disease.

Trial results: In ALKOVE-1, which had no comparison group, tumors shrank in 49% of 67 people after alectinib alone and 32% of 155 after 2 or more ALK inhibitors.

Approval type: Accelerated approval rests on early results such as response rates. The FDA lists ALKAZAR, a first-line trial against alectinib, as the study that must confirm the benefit of Nelkarmi.

How it is taken: The dose is 150mg by mouth once a day, with or without food.

More: Nelkarmi drug page

Source: FDA, November 17, 2026; Nelkarmi label, Nuvalent, November 2026; FDA ongoing cancer accelerated approvals

Which ALK inhibitor is approved after surgery for early-stage lung cancer?

Alecensa (alectinib) is the only ALK inhibitor approved as adjuvant treatment, meaning treatment after surgery to lower the chance the cancer comes back.

Who it is for: Adults whose ALK-positive lung cancer was removed by surgery, with tumors 4cm or larger or cancer in the lymph nodes. The ALK change must be found with a test of tumor tissue.

How long: The dose is 600mg twice a day with food for a total of 2 years, unless the cancer comes back or side effects become too hard to manage.

Trial results: In ALINA, the cancer came back, a new lung cancer appeared or the person died in 12% of 130 people on Alecensa and 39% of 127 on chemotherapy. Overall survival results were not yet mature.

Side effects: Liver side effects occurred in 61% in ALINA and were severe in 4.7%.

More: Alecensa drug page

Source: Alecensa label, DailyMed, August 2026

Are there clinical trials of new ALK drugs for lung cancer?

Yes. As of November 18, 2026, ALKAZAR and ALKOVE-1 for neladalkib were recruiting, along with several early studies of other ALK drugs at US sites.

First treatment: ALKAZAR (NCT06765109) compares neladalkib with Alecensa in about 450 people who have not taken an ALK inhibitor, with 22 of its 23 US sites recruiting.

After earlier ALK inhibitors: Astellas is testing gilteritinib (NCT07140016), a leukemia drug, at 9 US sites. TRIANA's TRI-611 (NCT07491497) is recruiting at 14 US sites, and Nuvectis is testing NXP900 with lorlatinib (NCT07784959).

Outside the US: Phase 3 trials of foritinib, TGRX-326 and SY-3505 against crizotinib are registered by sponsors in China, with no US sites listed.

More: ALK-positive lung cancer trials

Source: ClinicalTrials.gov NCT06765109; ClinicalTrials.gov NCT05384626; ClinicalTrials.gov NCT07140016; ClinicalTrials.gov NCT07491497; ClinicalTrials.gov NCT07784959; ClinicalTrials.gov NCT06569420; ClinicalTrials.gov NCT06082635; ClinicalTrials.gov NCT06254599

Go deeper

More on ALK-Positive Lung Cancer at Trial Friend

Sources

Where every number on this page comes from

Approved-drug facts are from the current FDA prescribing information on DailyMed or the FDA's own site, with the label's effective date. Investigational-drug facts are from ClinicalTrials.gov and the sources named in each row.

  1. Xalkori (crizotinib) prescribing information, Pfizer, label dated Oct 2026. DailyMed. Pivotal trial: ClinicalTrials.gov
  2. Zykadia (ceritinib) prescribing information, Novartis, label dated Oct 2026. DailyMed. Pivotal trial: ClinicalTrials.gov
  3. Alecensa (alectinib) prescribing information, Genentech (Roche), label dated Aug 2026. DailyMed. Pivotal trial: ClinicalTrials.gov
  4. Alunbrig (brigatinib) prescribing information, Takeda, label dated Jan 2026. DailyMed. Pivotal trial: ClinicalTrials.gov
  5. Lorbrena (lorlatinib) prescribing information, Pfizer, label dated Jun 2026. DailyMed. Pivotal trial: ClinicalTrials.gov
  6. Ensacove (ensartinib) prescribing information, Xcovery, label dated Feb 2026. DailyMed. Pivotal trial: ClinicalTrials.gov
  7. Nelkarmi (neladalkib) prescribing information, Nuvalent (GSK), label dated Nov 2026. FDA label. Pivotal trial: ClinicalTrials.gov
  8. Xospata (gilteritinib) for ALK-positive lung cancer, Astellas: ClinicalTrials.gov record. Checked November 18, 2026.

This page compares what the FDA labels and pivotal trials report. It is not medical advice, and no trial on this page compared these drugs with each other. Written and checked by Jason Hunter; the method is on the editorial standards page.